Barbara E Spencer1, Leonardino A Digma1, Robin G Jennings1, James B Brewer1,2. 1. Department of Neurosciences, University of California, San Diego, La Jolla, California, USA. 2. Department of Radiology, University of California, San Diego, La Jolla, California, USA.
Abstract
INTRODUCTION: Elevated β-amyloid is used to enroll individuals into preclinical Alzheimer's disease trials, but the screening process is inefficient and expensive. Novel enrichment methods are needed to improve efficiency of enrollment. METHODS: Alzheimer's disease incidence rates and a polygenic hazard score were used to create a gene- and age-defined ADAge. An ADAge cutpoint was chosen to optimally predict β-amyloid positivity among clinically normal Alzheimer's Disease Neuroimaging Initiative participants and applied to an independent Alzheimer's Disease Research Center validation cohort. The impact of ADAge enrichment on screening costs was evaluated in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease trial data. RESULTS: In the validation cohort, the ADAge-enriched sample had a higher proportion of individuals with elevated β-amyloid (difference [95% CI] 0.19[0.07 to 0.33]) than the unenriched sample. ADAge enrichment lowered screening costs by $4.41 million (31.00%) in the real-world clinical trial scenario. DISCUSSION: ADAge enrichment provides for a more efficient and cost-effective means to enroll clinically normal individuals with elevated β-amyloid in clinical trials.
INTRODUCTION: Elevated β-amyloid is used to enroll individuals into preclinical Alzheimer's disease trials, but the screening process is inefficient and expensive. Novel enrichment methods are needed to improve efficiency of enrollment. METHODS: Alzheimer's disease incidence rates and a polygenic hazard score were used to create a gene- and age-defined ADAge. An ADAge cutpoint was chosen to optimally predict β-amyloid positivity among clinically normal Alzheimer's Disease Neuroimaging Initiative participants and applied to an independent Alzheimer's Disease Research Center validation cohort. The impact of ADAge enrichment on screening costs was evaluated in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease trial data. RESULTS: In the validation cohort, the ADAge-enriched sample had a higher proportion of individuals with elevated β-amyloid (difference [95% CI] 0.19[0.07 to 0.33]) than the unenriched sample. ADAge enrichment lowered screening costs by $4.41 million (31.00%) in the real-world clinical trial scenario. DISCUSSION: ADAge enrichment provides for a more efficient and cost-effective means to enroll clinically normal individuals with elevated β-amyloid in clinical trials.
Authors: Kaj Blennow; Niklas Mattsson; Michael Schöll; Oskar Hansson; Henrik Zetterberg Journal: Trends Pharmacol Sci Date: 2015-04-01 Impact factor: 14.819
Authors: Chin Hong Tan; Chun Chieh Fan; Elizabeth C Mormino; Leo P Sugrue; Iris J Broce; Christopher P Hess; William P Dillon; Luke W Bonham; Jennifer S Yokoyama; Celeste M Karch; James B Brewer; Gil D Rabinovici; Bruce L Miller; Gerard D Schellenberg; Karolina Kauppi; Howard A Feldman; Dominic Holland; Linda K McEvoy; Bradley T Hyman; David A Bennett; Ole A Andreassen; Anders M Dale; Rahul S Desikan Journal: Acta Neuropathol Date: 2017-11-24 Impact factor: 17.088
Authors: E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance Journal: Science Date: 1993-08-13 Impact factor: 47.728
Authors: Willemijn J Jansen; Rik Ossenkoppele; Dirk L Knol; Betty M Tijms; Philip Scheltens; Frans R J Verhey; Pieter Jelle Visser; Pauline Aalten; Dag Aarsland; Daniel Alcolea; Myriam Alexander; Ina S Almdahl; Steven E Arnold; Inês Baldeiras; Henryk Barthel; Bart N M van Berckel; Kristen Bibeau; Kaj Blennow; David J Brooks; Mark A van Buchem; Vincent Camus; Enrica Cavedo; Kewei Chen; Gael Chetelat; Ann D Cohen; Alexander Drzezga; Sebastiaan Engelborghs; Anne M Fagan; Tormod Fladby; Adam S Fleisher; Wiesje M van der Flier; Lisa Ford; Stefan Förster; Juan Fortea; Nadia Foskett; Kristian S Frederiksen; Yvonne Freund-Levi; Giovanni B Frisoni; Lutz Froelich; Tomasz Gabryelewicz; Kiran Dip Gill; Olymbia Gkatzima; Estrella Gómez-Tortosa; Mark Forrest Gordon; Timo Grimmer; Harald Hampel; Lucrezia Hausner; Sabine Hellwig; Sanna-Kaisa Herukka; Helmut Hildebrandt; Lianna Ishihara; Adrian Ivanoiu; William J Jagust; Peter Johannsen; Ramesh Kandimalla; Elisabeth Kapaki; Aleksandra Klimkowicz-Mrowiec; William E Klunk; Sebastian Köhler; Norman Koglin; Johannes Kornhuber; Milica G Kramberger; Koen Van Laere; Susan M Landau; Dong Young Lee; Mony de Leon; Viviana Lisetti; Alberto Lleó; Karine Madsen; Wolfgang Maier; Jan Marcusson; Niklas Mattsson; Alexandre de Mendonça; Olga Meulenbroek; Philipp T Meyer; Mark A Mintun; Vincent Mok; José Luis Molinuevo; Hanne M Møllergård; John C Morris; Barbara Mroczko; Stefan Van der Mussele; Duk L Na; Andrew Newberg; Agneta Nordberg; Arto Nordlund; Gerald P Novak; George P Paraskevas; Lucilla Parnetti; Gayan Perera; Oliver Peters; Julius Popp; Sudesh Prabhakar; Gil D Rabinovici; Inez H G B Ramakers; Lorena Rami; Catarina Resende de Oliveira; Juha O Rinne; Karen M Rodrigue; Eloy Rodríguez-Rodríguez; Catherine M Roe; Uros Rot; Christopher C Rowe; Eckart Rüther; Osama Sabri; Páscual Sanchez-Juan; Isabel Santana; Marie Sarazin; Johannes Schröder; Christin Schütte; Sang W Seo; Femke Soetewey; Hilkka Soininen; Luiza Spiru; Hanne Struyfs; Charlotte E Teunissen; Magda Tsolaki; Rik Vandenberghe; Marcel M Verbeek; Victor L Villemagne; Stephanie J B Vos; Linda J C van Waalwijk van Doorn; Gunhild Waldemar; Anders Wallin; Åsa K Wallin; Jens Wiltfang; David A Wolk; Marzena Zboch; Henrik Zetterberg Journal: JAMA Date: 2015-05-19 Impact factor: 56.272
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk Journal: Alzheimers Res Ther Date: 2019-04-22 Impact factor: 6.982
Authors: J C Lambert; C A Ibrahim-Verbaas; D Harold; A C Naj; R Sims; C Bellenguez; A L DeStafano; J C Bis; G W Beecham; B Grenier-Boley; G Russo; T A Thorton-Wells; N Jones; A V Smith; V Chouraki; C Thomas; M A Ikram; D Zelenika; B N Vardarajan; Y Kamatani; C F Lin; A Gerrish; H Schmidt; B Kunkle; M L Dunstan; A Ruiz; M T Bihoreau; S H Choi; C Reitz; F Pasquier; C Cruchaga; D Craig; N Amin; C Berr; O L Lopez; P L De Jager; V Deramecourt; J A Johnston; D Evans; S Lovestone; L Letenneur; F J Morón; D C Rubinsztein; G Eiriksdottir; K Sleegers; A M Goate; N Fiévet; M W Huentelman; M Gill; K Brown; M I Kamboh; L Keller; P Barberger-Gateau; B McGuiness; E B Larson; R Green; A J Myers; C Dufouil; S Todd; D Wallon; S Love; E Rogaeva; J Gallacher; P St George-Hyslop; J Clarimon; A Lleo; A Bayer; D W Tsuang; L Yu; M Tsolaki; P Bossù; G Spalletta; P Proitsi; J Collinge; S Sorbi; F Sanchez-Garcia; N C Fox; J Hardy; M C Deniz Naranjo; P Bosco; R Clarke; C Brayne; D Galimberti; M Mancuso; F Matthews; S Moebus; P Mecocci; M Del Zompo; W Maier; H Hampel; A Pilotto; M Bullido; F Panza; P Caffarra; B Nacmias; J R Gilbert; M Mayhaus; L Lannefelt; H Hakonarson; S Pichler; M M Carrasquillo; M Ingelsson; D Beekly; V Alvarez; F Zou; O Valladares; S G Younkin; E Coto; K L Hamilton-Nelson; W Gu; C Razquin; P Pastor; I Mateo; M J Owen; K M Faber; P V Jonsson; O Combarros; M C O'Donovan; L B Cantwell; H Soininen; D Blacker; S Mead; T H Mosley; D A Bennett; T B Harris; L Fratiglioni; C Holmes; R F de Bruijn; P Passmore; T J Montine; K Bettens; J I Rotter; A Brice; K Morgan; T M Foroud; W A Kukull; D Hannequin; J F Powell; M A Nalls; K Ritchie; K L Lunetta; J S Kauwe; E Boerwinkle; M Riemenschneider; M Boada; M Hiltuenen; E R Martin; R Schmidt; D Rujescu; L S Wang; J F Dartigues; R Mayeux; C Tzourio; A Hofman; M M Nöthen; C Graff; B M Psaty; L Jones; J L Haines; P A Holmans; M Lathrop; M A Pericak-Vance; L J Launer; L A Farrer; C M van Duijn; C Van Broeckhoven; V Moskvina; S Seshadri; J Williams; G D Schellenberg; P Amouyel Journal: Nat Genet Date: 2013-10-27 Impact factor: 38.330
Authors: Kellen K Petersen; Richard B Lipton; Ellen Grober; Christos Davatzikos; Reisa A Sperling; Ali Ezzati Journal: Neurology Date: 2022-04-25 Impact factor: 11.800